KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. - Wikidata - wikimedia - TriplyDB

KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer.

KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer.

http://www.wikidata.org/entity/Q39347740

about

Translational progress on tumor biomarkers The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: new therapeutic targets Trespassing cancer cells: 'fingerprinting' invasive protrusions reveals metastatic culprits Switching Roles of TGF-β in Cancer Development: Implications for Therapeutic Target and Biomarker Studies Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotini SOX2 enhances the migration and invasion of ovarian cancer cells via Src kinase A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties.A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer.Metabolic markers and microecological characteristics of tongue coating in patients with chronic gastritis PTK6 promotes cancer migration and invasion in pancreatic cancer cells dependent on ERK signaling.PEAK1 Acts as a Molecular Switch to Regulate Context-Dependent TGFβ Responses in Breast Cancer.The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling.A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts.Dynamic phosphorylation of tyrosine 665 in pseudopodium-enriched atypical kinase 1 (PEAK1) is essential for the regulation of cell migration and focal adhesion turnover A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients.Role of CYB5A in pancreatic cancer prognosis and autophagy modulation KRas, ROS and the initiation of pancreatic cancer Roadblocks to translational advances on metastasis research.Pancreatic cancer stem cells: regulatory networks in the tumor microenvironment and targeted therapy.MS/MS-based strategies for proteomic profiling of invasive cell structures.Contribution of phosphoproteomics in understanding SRC signaling in normal and tumor cells.ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer.eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.Cellular and molecular aspects of pancreatic cancer.Homo- and Heterotypic Association Regulates Signaling by the SgK269/PEAK1 and SgK223 Pseudokinases Targeting metastasis.Controlling Directed Protein Interaction Networks in Cancer.Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC.Structure of SgK223 pseudokinase reveals novel mechanisms of homotypic and heterotypic association.The crystal structure of pseudokinase PEAK1 (Sugen Kinase 269) reveals an unusual catalytic cleft and a novel mode of kinase fold dimerization.The pseudokinases SgK269 and SgK223: A novel oncogenic alliance in human cancer.KRAS oncoprotein expression is regulated by a self-governing eIF5A-PEAK1 feed-forward regulatory loop.Ascending the PEAK1 toward targeting TGFβ during cancer progression: Recent advances and future perspectives.Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity.PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d.Pseudopodium-enriched atypical kinase 1 mediates angiogenesis by modulating GATA2-dependent VEGFR2 transcription.

P2860

Q26777676-B96CD972-9FDC-4F48-A900-2F8D4D13D76D Q26782593-04849480-85BA-4AB1-B0F2-D37483E13121 Q26997307-3DBD33C8-F5B4-4F59-B8BB-7A62ECBE6DB8 Q28079488-B94EDE81-1A02-489B-9750-F027706BE978 Q28650700-1445EB90-6DE8-48BD-8E78-1C6F17D6B93E Q33416585-DF388A8C-2121-4461-A3BB-D9D4F8109841 Q33768815-756CDE57-D503-4E41-A64C-1B73B19FE119 Q34376382-19B81CD1-9B4B-4B96-B60A-324660A34AF0 Q34518559-5C446E5C-D5E9-4ED2-9BFC-45AB26BD6C9B Q34680322-77C4C927-8F1A-49BF-BE4D-A17EA7EFECD8 Q34990849-0B3F3D33-B21F-4816-923D-4F793F432362 Q35161670-D1411BDB-D3B5-438B-A68E-E3BC9FF408D9 Q35744180-23AC2E2E-B287-4821-8E4C-D8A162159F6C Q35896807-58429B90-B9AB-4A1A-8E92-B9E1D3DEFDAC Q36125108-A61531E3-BFF6-4001-A46D-6CEC160F3A71 Q36508540-81FF489A-5E5C-4A40-8864-792A164560CA Q37224355-B2BED069-5367-43BF-8A7F-1314B9439E5A Q37253577-5CADDAF5-55CC-436A-8C62-EF761EDAC432 Q37532658-3E5920B1-6420-4703-B604-E2C0117A76ED Q37673906-B45CA5BA-005D-430A-B32B-3EFDAADA8DB0 Q37679393-84049456-F227-4666-A1FF-599E5BE39013 Q38033459-A2E6CC18-B372-4A06-968A-47483782143A Q38258895-CE9EE6FA-E814-4A7C-A044-79A04DBE7A27 Q38268873-DF4A769C-C652-4181-8B64-86427EC4DC70 Q38601572-F96C96E1-9CC5-4944-ADB1-C0D0C8E259EB Q38708727-45D563BD-5AE9-4DF8-99C9-4C911474DF25 Q38730160-76BB46B0-4565-4A13-BAEB-217D2DBD800F Q38751467-30A4616B-B11D-40EE-96BD-A3CA41B9C12F Q38786658-A7319976-F1A8-455F-8129-A31540671E3E Q41605713-0C07F038-DA84-4308-BB0A-18CAB1C70370 Q42340129-E33EFE50-F55A-42E7-B1FD-567FEADC8E0B Q42611868-A7BD8A67-7AE3-493A-9FF2-6395FB9DDCD2 Q47322504-B3757DA4-4842-4470-B36B-B9336F856542 Q47438670-D7DB2B30-EDAA-4A5D-B2F7-E136A61B9A51 Q48542758-F7794A3E-4422-4DA1-8201-BB3ED249DE77 Q49385083-DE71B878-11FD-490E-8FA0-1F0D277E2572 Q49887912-8592F13C-B124-420F-805C-3C262EBFB9E7 Q49959181-94B77D90-E91E-4975-8BC8-C702168F574C Q54959791-121178DA-89BA-4485-909F-D8CCFCD34E5E

P2860

KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer.

http://www.wikidata.org/entity/Q39347740

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

KRas induces a Src/PEAK1/ErbB2 ...... sistance in pancreatic cancer.

@en

KRas induces a Src/PEAK1/ErbB2 ...... sistance in pancreatic cancer.

@nl

type

label

KRas induces a Src/PEAK1/ErbB2 ...... sistance in pancreatic cancer.

@en

KRas induces a Src/PEAK1/ErbB2 ...... sistance in pancreatic cancer.

@nl

prefLabel

KRas induces a Src/PEAK1/ErbB2 ...... sistance in pancreatic cancer.

@en

KRas induces a Src/PEAK1/ErbB2 ...... sistance in pancreatic cancer.

@nl

P1433

Q39347740-11F94ACA-A6F6-4CBD-845A-0857C35668AE

P1476

Q39347740-4D956BC6-28C3-4EBD-82E8-EBA29DDE9C35

P2093

Q39347740-09ABBE03-83C6-49A1-B541-FA38197DA431

Q39347740-13E5BF39-CF45-45E9-9637-560B6F8F786D

Q39347740-189C8A38-49CF-410C-A351-1BEC3A220625

Q39347740-30BB5567-16F8-47D7-9106-4B9AE7A5237F

Q39347740-34C3BE67-1B23-4320-B58F-19594504BABF

Q39347740-3899D066-9D78-42CC-986B-6CCEBDE4D260

Q39347740-3C52CD40-CE51-4C51-BAE5-D22061B8B789

Q39347740-44C1F8CB-DAC9-429D-B0F3-CE30A564A648

Q39347740-68CB0B4B-3689-457A-B808-8398C829D2AF

Q39347740-6DB1CEC6-A28E-4FDC-8819-02E8245DE8CC

P2860

Q39347740-0CAE7892-F6AB-46AD-A30A-366EA31C0362

Q39347740-1293C528-3E6C-4007-AB60-A5E980AF0ED7

Q39347740-12A623CB-F30B-4549-A0BA-38EE1BB1F084

Q39347740-18DF719F-37E4-44A4-9891-52B914167658

Q39347740-1B268818-63A5-428A-9FCE-61A3308CA006

Q39347740-20673A3D-29E6-4242-97C3-CDE1A1A8DC56

Q39347740-2867BF44-32CA-42BA-8AB0-0D3DE63686B3

Q39347740-312D598E-EC8A-4CA9-8EB7-0476D93B2532

Q39347740-4D4CD465-6EEB-4696-BAA2-EEE698C2583C

Q39347740-4F533EB3-5FCD-4001-B1BE-1C23C6F6B219

P304

Q39347740-580845FB-9717-4078-A47C-BB980737C6BF

P31

Q39347740-1F17CF2F-7681-4CEE-8811-10A963860991

P356

Q39347740-2272D057-2A4A-4B74-B672-7B2986BE621E

P407

Q39347740-DF8A3403-C401-46B2-A310-E68C90A7CFC0

P433

Q39347740-0A6C7E9E-A5AD-41DF-88E0-940D6F0DE9F0

P478

Q39347740-BE8BCF48-8D22-4A71-9AB4-F68D8D71E51D

P577

Q39347740-D09159B7-B5BF-4A58-8D29-0859C10EB5E4

P698

Q39347740-A7EB58E6-A958-4694-BD98-26D3AA81B43C

P932

Q39347740-AD49F0B8-9492-4C81-9DCF-6F85A2C06A86

P356

0008-5472.CAN-11-3552

P1433

Cancer Research

P1476

KRas induces a Src/PEAK1/ErbB2 ...... sistance in pancreatic cancer.

@en

P2093

Andrew M Lowy

http://www.w3.org/2001/XMLSchema#string

Cristina Metildi

http://www.w3.org/2001/XMLSchema#string

Evangeline Mose

http://www.w3.org/2001/XMLSchema#string

Frederick D Park

http://www.w3.org/2001/XMLSchema#string

Jessica M Weems

http://www.w3.org/2001/XMLSchema#string

Jonathan A Kelber

http://www.w3.org/2001/XMLSchema#string

Konstantin Stoletov

http://www.w3.org/2001/XMLSchema#string

Michael Bouvet

http://www.w3.org/2001/XMLSchema#string

Richard L Klemke

http://www.w3.org/2001/XMLSchema#string

Robert M Hoffman

http://www.w3.org/2001/XMLSchema#string

P2860

Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected].

The protein kinase complement of the human genome

Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer

Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse

NetworKIN: a resource for exploring cellular phosphorylation networks

Recent progress of Src SH2 and SH3 inhibitors as anticancer agents.

c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential.

Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia.

Complementarity of ultrasound and fluorescence imaging in an orthotopic mouse model of pancreatic cancer.

P304

2554-2564

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-11-3552

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22589274

http://www.w3.org/2001/XMLSchema#string

P932

3366503

http://www.w3.org/2001/XMLSchema#string